QubeCo Biologics applies Mendelian randomization and advanced antibody engineering to discover and develop novel therapies for chronic kidney disease and other unmet needs. Its pipeline includes first-in-class bispecific antibody programs guided by strong genetic validation
Status: Stealth
Location: Belgium
Board director: Alexander Demoulin - Debora Dumont - Joris Vanderlocht
Board observer: Alexander Demoulin
Related news
No related news at the moment